Printer Friendly

C O R R E C T I O N -- AGOURON PHARMACEUTICALS.

 /C O R R E C T I O N -- AGOURON PHARMACEUTICALS/
 In SD001, Agouron Pharmaceuticals, moved earlier today, we are


advised by the company that the fourth paragraph should read, "Cohen will replace Theodor Heinrichs, who has retired from Agouron's board of directors after six years of service" instead of "...after eight years of service" as originally issued.
 -0- 3/19/92 C SD001
 (AGPH) CO: Agouron Pharmaceuticals Inc. ST: California IN: MTC SU: PER


CH -- SD001X -- 9621 03/19/92 11:16 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 19, 1992
Words:85
Previous Article:AT&T ANNOUNCES NEW LONG-DISTANCE SERVICE FOR AMERICANS TRAVELING OR LIVING ABROAD
Next Article:RECESSION THREATENS ENVIRONMENTAL CLEANUP EFFORTS; ENVIRONMENTAL BUSINESS EXECUTIVES GATHER TO SHARE STRATEGIES FOR SUCCESS
Topics:


Related Articles
AGOURON PHARMACEUTICALS CLEARED TO COMMENCE CLINICAL TESTING OF PSORIASIS DRUG
AGOURON PHARMACEUTICALS BEGINS CLINICAL TESTING OF PSORIASIS DRUG
AGOURON SCIENTISTS REPORT RATIONAL DESIGN OF NEW ANTI-TUMOR DRUG
FDA AUTHORIZES CLINICAL TESTING OF SECOND AGOURON ANTI-TUMOR DRUG
SPI PHARMACEUTICALS ANNOUNCES SECOND QUARTER DIVIDEND
AGOURON SUSPENDS DEVELOPMENT OF PSORIASIS AGENT
AGOURON PHARMACEUTICALS EXPANDS CLINICAL TESTING OF SECOND CANCER DRUG INTO UNITED STATES
AGOURON INITIATES PHASE II EFFICACY TRIALS OF ANTI-TUMOR DRUG AG337
AGOURON AND ROCHE TO COLLABORATE ON CANCER DRUGS
Agouron Reports Recent Results From Testing of Two Anticancer Drugs

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters